Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioblastoma × Interleukin-2 × Clear all
NCT01082926 2015-06-08

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

City of Hope Medical Center

Phase 1 Completed
6 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Neuroectodermal Tumors, Primitive, Gliosarcoma